Targeting LARP1 Suppresses Endometrial Cancer Growth and enhances Carboplatin Sensitivity
This study demonstrates that LARP1 acts as an oncogenic driver in endometrial cancer by promoting tumor growth and carboplatin resistance through E2F1 regulation, suggesting that targeting LARP1 could suppress tumor progression and enhance chemotherapy sensitivity.